Navigation Links
Stopping Controversial Asthma Drugs Could Have Downside: Study

By Randy Dotinga
HealthDay Reporter

MONDAY, Aug. 27 (HealthDay News) -- It's OK for some patients with asthma to stick with a combination of medications instead of abandoning one because of concerns about complications, a new analysis of existing research suggests.

The U.S. Food and Drug Administration has warned that asthma patients who take both long-acting beta-agonist and inhaled corticosteroid medications should be cautious about using them together once their condition is under control.

Long-acting beta-agonists -- such as drugs known by the brand names Serevent, Foradil and Brovana -- could cause side effects, the FDA cautioned, as could combination drugs. For that reason, the agency suggested that patients consider going with inhaled corticosteroids alone.

However, the new analysis came to a different conclusion. "Adding a long-acting beta-agonist to an inhaled corticosteroid medication makes a lot of sense in a number of patients since you get better control of the disease," said Dr. Thomas Casale, chief of allergy and immunology at Creighton University, and lead author of the report.

The report was published online Aug. 27 in the journal Archives of Internal Medicine.

At issue is how to best treat adults and older children who suffer from moderate to severe asthma.

Inhaled corticosteroids, which come in inhalers and are known by brand names such as Azmacort and Flovent, are often prescribed by themselves to reduce wheezing and other symptoms. They're usually taken daily but don't relieve asthma attacks when they're occurring. (Short-acting beta-agonists, such as the drug albuterol, treat asthma attacks themselves.)

The newer long-acting beta-agonists are frequently used with inhaled corticosteroids. Some medications, sold under the brand names Symbicort and Advair, combine both types of drugs.

This latest analysis, which examined five studies involving patients aged 15 or older, found that removing a long-acting beta-agonist -- but continuing treatment with an inhaled corticosteroid -- was worse for patients than continuing both drugs.

Patients who dropped the long-acting beta-agonists reported more asthma problems and fewer days with no symptoms. The findings also suggested that these patients needed more treatment of asthma attacks. The studies, however, didn't allow researchers to examine the risk of death under the different approaches.

Casale said he doesn't think the FDA's concerns about death and other health problems -- which resulted in a bold warning on drug labels -- have deterred physicians from prescribing the combination treatments. However, he said, they have reinforced guidelines recommending against using the long-acting beta-agonists as treatments by themselves.

"I think all of us agree with that," he said. "They're only to be used in conjunction with an inhaled corticosteroid, and only in those who aren't adequately controlled."

In an accompanying journal editorial, Dr. Chee Chan and Dr. Andrew Shorr, both from the division of pulmonary and critical care medicine at Washington Hospital Center in Washington D.C., wrote that they hoped the analysis "helps to lift some of the black clouds" in the debate over the use of the asthma drugs.

More information

For more about asthma, visit the U.S. National Library of Medicine.

SOURCES: Thomas B. Casale, M.D., professor of medicine and chief, allergy and immunology, Creighton University, Omaha, Neb.; Aug. 27, 2012, Archives of Internal Medicine, online

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat
2. Stopping and starting cancer cell cycle weakens and defeats multiple myeloma
3. Opioid receptors as a drug target for stopping obesity
4. U.S. Gives Green Light to Publish Controversial Bird Flu Research
5. Controversial vaccine trial should never have been run in India, researchers say
6. Supreme Court Backs Much of Controversial Health Reform Law
7. Rapid Asthma Treatment in ER May Prevent Admission
8. Some Schools Dont Let Kids Carry Asthma Inhalers
9. Secondhand smoke continues to vex children with asthma
10. Many Asthmatic Kids Harmed by Secondhand Smoke: Study
11. Seniors Undertreated for Asthma, and Many Skip Inhalers: Study
Post Your Comments:
Related Image:
Stopping Controversial Asthma Drugs Could Have Downside: Study
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: